GoodRx Holdings, Inc.

Ladies and gentlemen, thank you for standing by, and welcome to the GoodRx second quarter 2021 earnings conference call. As a reminder, today's conference is being recorded. I would now like to introduce your host for today's call, Whitney Notaro, Vice President of Investment Relations. Ms. Notaro, you may begin.

Thank you, Operator. Good morning, everyone, and welcome to GoodRx's earnings conference call for the second quarter of 2021. Joining me today are Doug Hirsch and Trevor Bezdek, our co-founders and co-chief executive officers, Karsten Bowerman, our chief financial officer, and Bansi Nagy, our president of healthcare. Before we begin, I'd like to remind everyone that this call will contain forward-looking statements. All statements made on this call that do not relate to matters of historical fact should be considered forward-looking statements. including statements regarding management's plans, strategies, goals, and objectives, our market opportunity, our anticipated financial performance, our manufacturer solutions offering, and the expected impact of COVID-19 on our business. These statements are neither promises nor guarantees, but involve known and unknown risks, uncertainties, and other important factors. These factors may cause our actual results, performance, or achievements to be materially different for many future results, performance, or achievements expressed or implied by the forward-looking statement. Factors discussed in the risk factors section of our quarterly report on Form 10-Q for the quarter ended June 30, 2021, an annual report on Form 10-K for the year ended December 31, 2020, and our other filings with the Securities and Exchange Commission could cause actual results to differ materially from those indicated by the forward-looking statements made on this call. Any such forward-looking statements represent management's estimates as of the date of this call, and we disclaim any obligation to update these statements, even if subsequent events cause our views to change. In addition, we may also reference certain non-GAAP metrics, which are reconciled to the nearest GAAP metric in the company's shareholder letter, which can be found on the overview page of our investor relations website at investors.gooderx.com. I'd also like to remind everyone the replay of this call will become available there shortly as well. With that, I'll turn the call over to Trevor.

Thank you, Whitney, and thanks to everyone for joining us this morning. I'm proud to report another quarter of strong performance for GoodRx. Our track record of strong, profitable growth continued in the second quarter, with revenue growing 43% year over year, a rapid reacceleration relative to average growth of approximately 31% for the trailing 12 months through March. This combined with an adjusted EBITDA margin of 30.9% makes us what many call a rule of 70 company, much better than a traditional rule of 41, which we believe is unique at our size and in our space. Revenue grew to a record $176.6 million, even while we believe the backlog of undiagnosed conditions continued to grow. In fact, in our prescription transactions offering, our monthly active consumers grew a solid 36% year over year. Adding subscribers to that figure, our aggregate prescription-related user growth was above 40% year over year. These positive results were fueled by our ability to extend our platform, from our historical focus on prescription discounts to today, where we impact almost 20 million Americans a month, including healthcare professionals who make up about 17% of our website visitors, and have built successful subscriptions, pharma manufacturer solutions, and telehealth offerings that are growing rapidly. almost doubling and tripling respectively in the case of the first two. A growing extensible platform is the foundation allowing us to continuously offer even more valuable services to our healthcare providers and consumers. For example, our Surescripts relationship, which Doug will discuss further, allows us to serve healthcare providers and their patients by providing real-time drug discount pricing in electronic health record systems that delivered almost 2 billion prescriptions last year. Another example is our strategic agreement with GoHelp, which marks an exciting first step into the insurance marketplace space for us. And within GoodRx Gold, our subscription program that provides two times the LTV of our prescription transactions offering, we now offer Gold at Rite Aid's over 2,000 pharmacies. We continue to be excited about the rapid evolution of our prescription transactions offering as well. Between it and our subscriptions offering, We helped a record 7.5 million consumers save on their prescriptions by using CoderX at one of our 70,000 participating pharmacies. We also expanded the marketplace with the addition of additional PDMs to our network. I couldn't be more pleased with our results or the progress we are making toward our goal of reinventing digital health. As Carson will discuss shortly, we expect nearly 40% revenue growth in the third quarter. The strength of the relationships we've built with healthcare providers, pharmacists, and pharmacies pharma manufacturers, and most importantly, consumers, in combination with our highly accessible platform and offering, puts us in a great position for years to come. With that, I'll turn the call over to Doug, who will speak to some recent successes that further our mission to help Americans get the healthcare they need at a price they can afford.